Please login to the form below

Not currently logged in
Email:
Password:

inflammatory disorders

This page shows the latest inflammatory disorders news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Roche enters NASH race with deal to buy Jecure

NLRP3 is a protein thought to be involved in the formation of “inflammosomes”, protein complexes involved in cellular inflammatory responses. ... Feldstein – sits apart from rival therapies and could have applications beyond NASH in other

Latest news

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    disorders. With a headline value of $102.25m, Receptor will be undertaking manufacture and commercialisation. ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions such as chronic pain,

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Pharma deals during March 2013 Pharma deals during March 2013

    25. Five Prime Therapeutics/ UCB. Option to license. Protein discovery platform - up to 5 programmes for fibrosis-related inflammatory diseases and CNS disorders.

  • Interview: Michel Goldman, Innovative Medicines Initiative Interview: Michel Goldman, Innovative Medicines Initiative

    And we do this by implementing proposals in different areas. For example, we have several projects on brain disorders, diabetes, cancer, inflammatory disorders and several projects on pulmonary diseases, to give ... His achievements in the fields of

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

    He has 30 years’ experience in research and development specifically in gastrointestinal disorders, inflammatory diseases and cancers, and previously co-founded Synergy Pharmaceuticals and served as its chief scientific officer.

  • Karus names two division heads Karus names two division heads

    Most recently he was VP, global head – respiratory disease. In his new role Dr Finan will work on Karus' most advanced programme, a treatment for inflammatory disorders.

  • Merck KGaA appoints biosimilar head Merck KGaA appoints biosimilar head

    From March 1, Sturge will run the company's biosimilars division, which was set up in 2012 to develop copies of biological treatments with a focus on oncology and inflammatory disorders. .

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    His main responsibilities will include identifying potential partnerships and acquisitions for the company, which specialises in developing treatments for difficult-to-treat autoimmune and inflammatory disorders.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics